Abstract
As potential alternatives to conventional antibiotics, antimicrobial peptides have attracted great attention in recent years. This review provides an overview of their characteristics and mechanisms of action, summarizes the current progress in clinical research and challenges in clinical utility. Antimicrobial peptides display robust activity against a wide variety of pathogens, including multidrug resistant bacteria, and are less susceptible to resistance development. Dozens of antimicrobial peptides are currently in various stages of clinical trials. However, some intrinsic drawbacks limit their clinical utility: toxicity, stability and manufacturing costs. Researchers have tried to modify the structure of antimicrobial peptides and worked on developing peptidomimetics. It is believed that antimicrobial peptides and peptidomimetics will play an important role against multidrug resistant bacteria in the future. Key words: Dermcidins; Infection; Drug resistance; Clinical Trial; Peptidomimetics
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
